Cui Zhixin, Xie Ruijie, Lu Xiaoting, Schomburg Lutz, Brenner Hermann, Schöttker Ben
Division of Clinical Epidemiology and Aging Research, German Cancer Research Center, Im Neuenheimer Feld 581, 69120 Heidelberg, Germany; Medical Faculty Heidelberg, Heidelberg University, Im Neuenheimer Feld 672, 69120 Heidelberg, Germany.
Department of Clinical Nutrition, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Yanjiang West Road 107, 510120 Guangzhou, China.
Redox Biol. 2025 Jul 10;85:103755. doi: 10.1016/j.redox.2025.103755.
To provide a systematic review and meta-analysis of population-based cohort studies on the association of selenium status with all-cause and cause-specific mortality.
Relevant studies were identified through systematic searches of MEDLINE and ISI Web of Knowledge. Risk ratios (RRs) reported across categories of selenium biomarkers were recalculated as continuous RR estimations per standard deviation (SD) using generalized least squares for linear trend estimation and pooled in random effects meta-analyses.
The literature search identified 20 studies, including 17 studies on all-cause mortality, 9 studies on cardiovascular mortality and 7 on cancer mortality. An increase of selenium biomarker concentration by one SD was associated with 13 % lower all-cause mortality (RR [95 %-confidence interval], 0.87 [0.83-0.90]), 11 % lower cardiovascular mortality (0.89 [0.84-0.94]) and 15 % lower cancer mortality (0.85 [0.78-0.94]). Although moderate heterogeneity was observed, the inverse association with all-cause mortality was robust across countries with low or adequate selenium supply, selenium measurement methods, recruitment years, study quality scores, follow-up lengths and sample sizes. The trim and fill method showed no indications of relevant publication bias.
Selenium biomarkers are inversely associated with all-cause, cardiovascular and cancer mortality in the general population and clinical trials among selenium deficient populations are still needed.
对基于人群的队列研究进行系统评价和荟萃分析,以探讨硒水平与全因死亡率及特定病因死亡率之间的关联。
通过系统检索MEDLINE和ISI Web of Knowledge确定相关研究。使用广义最小二乘法进行线性趋势估计,将硒生物标志物各分类中报告的风险比(RRs)重新计算为每标准差(SD)的连续RR估计值,并纳入随机效应荟萃分析中进行合并。
文献检索共纳入20项研究,其中17项关于全因死亡率,9项关于心血管疾病死亡率,7项关于癌症死亡率。硒生物标志物浓度每增加1个标准差,全因死亡率降低13%(RR[95%置信区间],0.87[0.83 - 0.90]),心血管疾病死亡率降低11%(0.89[0.84 - 0.94]),癌症死亡率降低15%(0.85[0.78 - 0.94])。尽管观察到中度异质性,但在硒供应低或充足的国家、硒测量方法、招募年份、研究质量评分、随访时长和样本量等方面,与全因死亡率的负相关关系均较为稳健。修剪填充法未显示存在相关发表偏倚的迹象。
硒生物标志物与普通人群的全因、心血管疾病和癌症死亡率呈负相关,仍需要在缺硒人群中开展临床试验。